Insights into the sigma-1 receptor chaperone's cellular functions: A microarray report

Synapse

Volumn 66, Issue 1, 2012, Pages 42-51

  Tsai, Shang Yi ^a   Rothman, Richard Kyle ^a   Su, Tsung Ping ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

CNS; Microarray; Sigma receptor

Indexed keywords

ACTIN; CHAPERONE; COMPLEMENTARY DNA; CYTOCHROME; CYTOCHROME B245; CYTOCHROME C; CYTOCHROME P450; F ACTIN; FREE RADICAL; SIGMA 1 OPIATE RECEPTOR; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ACTIN POLYMERIZATION; ANIMAL CELL; ARTICLE; BRAIN NERVE CELL; CELL FUNCTION; CYTOSKELETON; GENE CONTROL; GENE EXPRESSION PROFILING; GENOME; HIPPOCAMPUS; MICROARRAY ANALYSIS; NERVE CELL CULTURE; NERVE CELL PLASTICITY; NEUROFILAMENT; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; STEROIDOGENESIS; UBIQUITINATION; UNINDEXED SEQUENCE;

ANIMALS; CELLS, CULTURED; GENE EXPRESSION PROFILING; HIPPOCAMPUS; MOLECULAR CHAPERONES; NEURONS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RATS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, SIGMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 81555228695     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20984     Document Type: Article

References (57)

1. Antonini VPO, Coradazzi M, Marrazzo A, Ronsisvalle S, Arena E, Leanza G. 2009. Anti-amnesic properties of (+/-)-PPCC, a novel sigma receptor ligand, on cognitive dysfunction induced by selective cholinergic lesion in rats. J Neurochem 109: 744-754.
2. Brigman JL, Wright T, Talani G, Prasad-Mulcare S, Jinde S, Seabold GK, Mathur P, Davis MI, Bock R, Gustin RM, Colbran RJ, Alvarez VA, Nakazawa K, Delpire E, Lovinger DM, Holmes A. 2010. Loss of GluN2B-containing NMDA receptors in CA1 hippocampus and cortex impairs long-term depression, reduces dendritic spine density, and disrupts learning. J Neurosci 30: 4590-4600.
3. Cobos EJ, Entrena JM, Nieto FR, Cendan CM, Del Pozo E. 2008. Pharmacology and therapeutic potential of sigma(1) receptor ligands. Curr Neuropharmacol 6: 344-366.
4. Gao HM, Hong JS. 2008. Why neurodegenerative diseases are progressive: Uncontrolled inflammation drives disease progression. Trends Immunol 29: 357-365.
5. Gekker G, Hu S, Sheng WS, Rock RB, Lokensgard JR, Peterson PK. 2006. Cocaine-induced HIV-1 expression in microglia involves sigma-1 receptors and transforming growth factor-beta1. Int Immunopharmacol 6: 1029-1033.
6. Goyagi T, Bhardwaj A, Koehler RC, Traystman RJ, Hurn PD, Kirsch JR. 2003. Potent sigma 1-receptor ligand 4-phenyl-1-(4-phenylbutyl) piperidine provides ischemic neuroprotection without altering dopamine accumulation in vivo in rats. Anesth Analg 96: 532-538.
7. Hall AA, Herrera Y, Ajmo CT Jr, Cuevas J, Pennypacker KR. 2009. Sigma receptors suppress multiple aspects of microglial activation. Glia 57: 744-754.
8. Hayashi T, Su TP. 2007. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. Cell 131: 596-610.
9. Hayashi T, Justinova Z, Hayashi E, Cormaci G, Mori T, Tsai SY, Barnes C, Goldberg SR, Su TP. 2010. Regulation of sigma-1 receptors and endoplasmic reticulum chaperones in the brain of methamphetamine self-administering rats. J Pharmacol Exp Ther 332: 1054-1063.
10. Hirsch EC, Hunot S. 2009. Neuroinflammation in Parkinson's disease: A target for neuroprotection? Lancet Neurol 8: 382-397.
11. Ishima T, Nishimura T, Iyo M, Hashimoto K. 2008. Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by donepezil: Role of sigma-1 receptors and IP3 receptors. Prog Neuropsychopharmacol Biol Psychiatry 32: 1656-1659.
12. Iyo MSY, Watanabe H, Fujisaki M, Miyatake R, Fukami G, Shiina A, Nakazato M, Shiraishi T, Ookami T, Hashimoto K. 2008. Fluvoxamine as a sigma-1 receptor agonist improved cognitive impairments in a patient with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 32: 1072-1073.
13. Jansen KL, Faull RL, Storey P, Leslie RA. 1993. Loss of sigma binding sites in the CA1 area of the anterior hippocampus in Alzheimer's disease correlates with CA1 pyramidal cell loss. Brain Res 623: 299-302.
14. Katnik C, Guerrero WR, Pennypacker KR, Herrera Y, Cuevas J. 2006. Sigma-1 receptor activation prevents intracellular calcium dysregulation in cortical neurons during in vitro ischemia. J Pharmacol Exp Ther 319: 1355-1365.
15. Kim SY, Volsky DJ. 2005. PAGE: Parametric analysis of gene set enrichment. BMC Bioinformatics 6: 144.
16. Kreutzberg GW. 1996. Microglia: A sensor for pathological events in the CNS. Trends Neurosci 19: 312-318.
17. Kunitachi S, Fujita Y, Ishima T, Kohno M, Horio M, Tanibuchi Y, Shirayama Y, Iyo M, Hashimoto K. 2009. Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent subchronic administration of donepezil: Role of sigma-1 receptors. Brain Res 1279: 189-196.
18. Liu Y, Matsumoto RR. 2008. Alterations in fos-related antigen 2 and sigma1 receptor gene and protein expression are associated with the development of cocaine-induced behavioral sensitization: Time course and regional distribution studies. J Pharmacol Exp Ther 327: 187-195.
19. Liu Y, Qin L, Li G, Zhang W, An L, Liu B, Hong JS. 2003. Dextromethorphan protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation. J Pharmacol Exp Ther 305: 212-218.
20. Liu Y, Chen GD, Lerner MR, Brackett DJ, Matsumoto RR. 2005. Cocaine up-regulates Fra-2 and sigma-1 receptor gene and protein expression in brain regions involved in addiction and reward. J Pharmacol Exp Ther 314: 770-779.
21. Luty AA, Kwok JB, Dobson-Stone C, Loy CT, Coupland KG, Karlstrom H, Sobow T, Tchorzewska J, Maruszak A, Barcikowska M, Panegyres PK, Zekanowski C, Brooks WS, Williams KL, Blair IP, Mather KA, Sachdev PS, Halliday GM, Schofield PR. 2010. Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degeneration-motor neuron disease. Ann Neurol 68: 639-649.
22. Lynch NJ, Willis CL, Nolan CC, Roscher S, Fowler MJ, Weihe E, Ray DE, Schwaeble WJ. 2004. Microglial activation and increased synthesis of complement component C1q precedes blood-brain barrier dysfunction in rats. Mol Immunol 40: 709-716.
23. Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE. 1976. The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 197: 517-532.
24. Martinez-Lara E, Siles E, Hernandez R, Canuelo AR, Luisa del Moral M, Jimenez A, Blanco S, Lopez-Ramos JC, Esteban FJ, Pedrosa JA, Peinado MA. 2003. Glutathione S-transferase isoenzymatic response to aging in rat cerebral cortex and cerebellum. Neurobiol Aging 24: 501-509.
25. Mavlyutov TA, Epstein ML, Andersen KA, Ziskind-Conhaim L, Ruoho AE. 2010. The sigma-1 receptor is enriched in postsynaptic sites of C-terminals in mouse motoneurons. An anatomical and behavioral study. Neuroscience 167: 247-255.
26. Meunier J, Maurice T. 2004. Beneficial effects of the sigma1 receptor agonists igmesine and dehydroepiandrosterone against learning impairments in rats prenatally exposed to cocaine. Neurotoxicol Teratol 26: 783-797.
27. Meunier J, Hayashi T. 2010. Sigma-1 receptors regulate Bcl-2 expression by reactive oxygen species-dependent transcriptional regulation of nuclear factor kappaB. J Pharmacol Exp Ther 332: 388-397.
28. Meunier J, Gue M, Recasens M, Maurice T. 2004. Attenuation by a sigma1 (sigma1) receptor agonist of the learning and memory deficits induced by a prenatal restraint stress in juvenile rats. Br J Pharmacol 142: 689-700.
29. Meunier J, Ieni J, Maurice T. 2006. The anti-amnesic and neuroprotective effects of donepezil against amyloid beta25-35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor. Br J Pharmacol 149: 998-1012.
30. Mishina M, Ohyama M, Ishii K, Kitamura S, Kimura Y, Oda K, Kawamura K, Sasaki T, Kobayashi S, Katayama Y, Ishiwata K. 2008. Low density of sigma1 receptors in early Alzheimer's disease. Ann Nucl Med 22: 151-156.
31. Nakano M, Osada K, Misonoo A, Fujiwara K, Takahashi M, Ogawa Y, Haga T, Kanai S, Tanaka D, Sasuga Y, Yanagida T, Asakura M, Yamaguchi N. 2010. Fluvoxamine and sigma-1 receptor agonists dehydroepiandrosterone (DHEA)-sulfate induces the Ser(473)-phosphorylation of Akt-1 in PC12 cells. Life Sci 86: 309-314.
32. Nguyen EC, McCracken KA, Liu Y, Pouw B, Matsumoto RR. 2005. Involvement of sigma (sigma) receptors in the acute actions of methamphetamine: Receptor binding and behavioral studies. Neuropharmacology 49: 638-645.
33. Power JH, Asad S, Chataway TK, Chegini F, Manavis J, Temlett JA, Jensen PH, Blumbergs PC, Gai WP. 2008. Peroxiredoxin 6 in human brain: Molecular forms, cellular distribution and association with Alzheimer's disease pathology. Acta Neuropathol 115: 611-622.
34. Qian L, Wu HM, Chen SH, Zhang D, Ali SF, Peterson L, Wilson B, Lu RB, Hong JS, Flood PM. 2011. {beta}2-Adrenergic receptor activation prevents rodent dopaminergic neurotoxicity by inhibiting microglia via a novel signaling pathway. J Immunol 186: 4443-4454.
35. Romieu P, Martin-Fardon R, Bowen WD, Maurice T. 2003. Sigma 1 receptor-related neuroactive steroids modulate cocaine-induced reward. J Neurosci 23: 3572-3576.
36. Roth MD, Whittaker KM, Choi R, Tashkin DP, Baldwin GC. 2005. Cocaine and sigma-1 receptors modulate HIV infection, chemokine receptors, and the HPA axis in the huPBL-SCID model. J Leukoc Biol 78: 1198-1203.
37. Rust MB, Gurniak CB, Renner M, Vara H, Morando L, Gorlich A, Sassoe-Pognetto M, Banchaabouchi MA, Giustetto M, Triller A, Choquet D, Witke W. 2010. Learning, AMPA receptor mobility and synaptic plasticity depend on n-cofilin-mediated actin dynamics. EMBO J 29: 1889-1902.
38. Sanchez C, Meier E. 1997. Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike? Psychopharmacology (Berl) 129: 197-205.
39. Schafer MK, Schwaeble WJ, Post C, Salvati P, Calabresi M, Sim RB, Petry F, Loos M, Weihe E. 2000. Complement C1q is dramatically up-regulated in brain microglia in response to transient global cerebral ischemia. J Immunol 164: 5446-5452.
40. Stefanski R, Justinova Z, Hayashi T, Takebayashi M, Goldberg SR, Su TP. 2004. Sigma1 receptor upregulation after chronic methamphetamine self-administration in rats: A study with yoked controls. Psychopharmacology (Berl) 175: 68-75.
41. Stranahan AM, Lee K, Becker KG, Zhang Y, Maudsley S, Martin B, Cutler RG, Mattson MP. 2010. Hippocampal gene expression patterns underlying the enhancement of memory by running in aged mice. Neurobiol Aging 31: 1937-1949.
42. Su TP, London ED, Jaffe JH. 1988. Steroid binding at sigma receptors suggests a link between endocrine, nervous, and immune systems. Science 240: 219-221.
43. Takebayashi M, Hayashi T, Su TP. 2002. Nerve growth factor-induced neurite sprouting in PC12 cells involves sigma-1 receptors: Implications for antidepressants. J Pharmacol Exp Ther 303: 1227-1237.
44. Takebayashi M, Hayashi T, Su TP. 2004. Sigma-1 receptors potentiate epidermal growth factor signaling towards neuritogenesis in PC12 cells: Potential relation to lipid raft reconstitution. Synapse 53: 90-103.
45. Takizawa RHK, Tochigi M, Kawakubo Y, Marumo K, Sasaki T, Fukuda M, Kasai K. 2009. Association between sigma-1 receptor gene polymorphism and prefrontal hemodynamic response induced by cognitive activation in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 33: 491-498.
46. Terai K, Walker DG, McGeer EG, McGeer PL. 1997. Neurons express proteins of the classical complement pathway in Alzheimer disease. Brain Res 769: 385-390.
47. Tsai SY, Hayashi T, Harvey BK, Wang Y, Wu WW, Shen RF, Zhang Y, Becker KG, Hoffer BJ, Su TP. 2009a. Sigma-1 receptors regulate hippocampal dendritic spine formation via a free radical-sensitive mechanism involving Rac1xGTP pathway. Proc Natl Acad Sci USA 106: 22468-22473.
48. Tsai SY, Hayashi T, Mori T, Su TP. 2009b. Sigma-1 receptor chaperones and diseases. Cent Nerv Syst Agents Med Chem 9: 184-189.
49. Tsatmali M, Walcott EC, Makarenkova H, Crossin KL. 2006. Reactive oxygen species modulate the differentiation of neurons in clonal cortical cultures. Mol Cell Neurosci 33: 345-357.
50. Tuerxun T, Numakawa T, Adachi N, Kumamaru E, Kitazawa H, Kudo M, Kunugi H. 2010. SA4503, a sigma-1 receptor agonist, prevents cultured cortical neurons from oxidative stress-induced cell death via suppression of MAPK pathway activation and glutamate receptor expression. Neurosci Lett 469: 303-308.
51. Vagnerova K, Hurn PD, Bhardwaj A, Kirsch JR. 2006. Sigma 1 receptor agonists act as neuroprotective drugs through inhibition of inducible nitric oxide synthase. Anesth Analg 103: 430-434.
52. Veerhuis R, Janssen I, Hack CE, Eikelenboom P. 1996. Early complement components in Alzheimer's disease brains. Acta Neuropathol 91: 53-60.
53. Veerhuis R, Janssen I, De Groot CJ, Van Muiswinkel FL, Hack CE, Eikelenboom P. 1999. Cytokines associated with amyloid plaques in Alzheimer's disease brain stimulate human glial and neuronal cell cultures to secrete early complement proteins, but not C1-inhibitor. Exp Neurol 160: 289-299.
54. Wang C, Huang Z, Du Y, Cheng Y, Chen S, Guo F. 2010. ATF4 regulates lipid metabolism and thermogenesis. Cell Res 20: 174-184.
55. Yang S, Bhardwaj A, Cheng J, Alkayed NJ, Hurn PD, Kirsch JR. 2007. Sigma receptor agonists provide neuroprotection in vitro by preserving bcl-2. Anesth Analg 104: 1179-1184.
56. Zhang F, Shi JS, Zhou H, Wilson B, Hong JS, Gao HM. 2010. Resveratrol protects dopamine neurons against lipopolysaccharide-induced neurotoxicity through its anti-inflammatory actions. Mol Pharmacol 78: 466-477.
57. Zhu LX, Sharma S, Gardner B, Escuadro B, Atianzar K, Tashkin DP, Dubinett SM. 2003. IL-10 mediates sigma 1 receptor-dependent suppression of antitumor immunity. J Immunol 170: 3585-3591.